Read Full Article
...tumor-selective immunotherapies for patients with cancer, today announced the appointment of Paul J. Clancy to its Board of Directors. Mr. Clancy is...
Paul is a highly respected leader in the biotechnology community and brings a wealth of strategic and operational experience that will support Xilio through this stage of rapid growth of the company.
Xilio Therapeutics is at an exciting stage in its growth trajectory and has the potential to be a leader in developing highly potent immunotherapies that are selectively activated in tumors.